Multiple Myeloma — ABC294640 (Opaganib) in Refractory / Relapsed Multiple Myeloma
Citation(s)
A Phase Ib/II Safety and Efficacy Study of ABC294640 in Patients With Refractory or Relapsed Multiple Myeloma Who Have Previously Been Treated With Proteasome Inhibitors and Immunomodulatory Drugs